检索结果-南通市图书馆

cDNA Expression Array Analysis of Gene Expression in Human Hepatocarcinoma Hep3B Cells Induced By BNIPL-1

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Acta Biochimica et Biophysica Sinica 2005年第9期37卷 618-624页

作者： li XIE~(1,2) Wen-Xin QIN~(2,3*) jin-jun li~(2,3) Xiang-Huo HE~1 Hui-Qun SHU~2 Gen-Fu yao~2 da-fang wan~(2,3*) jian-ren gu~~(2,3) 1 shanghai medical college,fudan university,shanghai 200032,china 2 National Laboratory for Oncogenes and Related Genes,shanghai Cancer Institute,shanghai 200032,china 3 Cancer Institute,shanghai Jiaotong Universiry,shanghai 200032,china shanghai medical college Fudan UniversityShanghai 200032 China National Laboratory for Oncogenes and Related Genes Shanghai Cancer InstituteShanghai 200032 China Cancer Institute Shanghai Jiaotong UniversityShanghai 200032 China

Bcl-2/adenovirus E1B 19 kda interacting protein 2 like-1 （BNIPL-1） is a novel human proteinidentified in our laboratory,which can interact with Bcl-2 and Cdc42GAP and induce apoptosis via theBNIP-2 and Cdc42GAP homology （BCH） *** the present study,we established the Hep3B-Tet-onstable cell line in which expression of BNIPL-1 can be induced by *** cell proliferationactivity assay showed that the overexpression of BNIPL-1 suppresses Hep3B cell growth in *** expression profiles of 588 known genes from BNIPL-1-transfected Hep3B-Tet-on and vectorcontrol cells were determined using the Atlas human cDNA expression *** genes were differentiallyexpressed between these two cell lines,among which seven genes were up-regulated and eight genes weredown-regulated by ***,the differential expression result was confirmed by *** these differentially expressed genes,p16INK4,IL-12,TRAIL and the lympbotoxin β geneinvolved in growth suppression or cell apoptosis were up-regulated,and PTEN involved in cell proliferationwas down-regulated by *** results suggest that BNIPL-1 might inhibit cell growth though cellcycle arrest and/or apoptotic cell death pathway（s）.

关键词： BNIPL-1 Tet-on Atlas human cDNA array apoptosis

CEPC Technical Design Report

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

Radiation Detection Technology and Methods 2024年第1期8卷 I0003-I0016,1-1091页

作者： Waleed Abdallah Tiago Carlos Adorno de Freitas Konstantin Afanaciev Shakeel Ahmad Ijaz Ahmed Xiaocong Ai Abid Aleem Wolfgang Altmannshofer Fabio Alves weiming An Rui An daniele Paolo Anderle Stefan Antusch Yasuo Arai Andrej Arbuzov Abdesslam Arhrib Mustafa Ashry Sha Bai Yu Bai Yang Bai Vipul Bairathi Csaba Balazs Philip Bambade Yong Ban Tripamo Bandyopadhyay Shou-Shan Bao Desmond P.Barber Ayse Bat Varvara Batozskaya Subash Chandra Behera Alexander Belyaev Michele Bertucci Xiao-jun Bi Yuanjie Bi Tianjian Bian Fabrizio Bianchi Thomas Biekotter Michela Biglietti Shalva Bilanishvili Deng Binglin Denis Bodrov Anton Bogomyagkov Serge Bondarenko Stewart Boogert Maarten Boonekamp Marcello Borri Angelo Bosotti Vincent Boudry Mohammed Boukidi Igor Boyko Ivanka Bozovic Giuseppe Bozzi Jean-Claude Brient Anastasiia Budzinskaya Masroor Bukhari Vladimir Bytev Giacomo Cacciapaglia Hua Cai Wenyong Cai Wujun Cai Yijian Cai Yizhou Cai Yuchen Cai Haiying Cai Huacheng Cai Lorenzo Calibbi junsong Cang guofu Cao jianshe Cao Antoine Chance Xuejun Chang Yue Chang Zhe Chang Xinyuan Chang wei Chao Auttakit Chatrabhuti Yimin Che Yuzhi Che Bin Chen danping Chen Fuqing Chen Fusan Chen Gang Chen guoming Chen Hua-Xing Chen Huirun Chen jinhui Chen Ji-Yuan Chen Kai Chen Mali Chen mingjun Chen mingshui Chen ning Chen Shanhong Chen Shanzhen Chen Shao-Long Chen Shaomin Chen Shiqiang Chen Tianlu Chen wei Chen Xiang Chen Xiaoyu Chen Xin Chen Xun Chen Xurong Chen Ye Chen Ying Chen Yukai Chen Zelin Chen Zilin Chen Gang Chen Boping Chen Chunhui Chen Hok Chuen Cheng Huajie Cheng Shan Cheng Tongguang Cheng Yunlong Chi Pietro Chimenti Wen Han Chiu guk Cho ming-Chung Chu Xiaotong Chu Ziliang Chu guglielmo Coloretti Andreas Crivellin Hanhua Cui Xiaohao Cui Zhaoyuan Cui Brunella D'Anzi ling-Yun dai Xinchen dai Xuwen dai Antonio De Maria Nicola De Filippis Christophe De La Taille Francesca De Mori Chiara De Sio Elisa Del Core Shuangxue Deng wei-Tian Deng Zhi Deng Ziyan Deng Bhupal Dev Tang Dewen Biagio Di Micco Ran Ding Siqin Dingl Yadong Ding Haiyi dong jianin AGH university of Science and Technology Faculty of Physics and Applied Computer ScienceKrakow Anhui university HefeiAnhui Applied Physics Department Federal Urdu University of ArtsScience and TechnologyIslamabad Banaras Hindu university Institute of ScienceVaranasi Bandirma Onyedi Eylul university Bandirma Beihang university Beijing Beijing Computational Science Research Center Beijing Beijing Conveyi LTD Beijing Beijing Glass Research Institute Co. LtdBeijing Beijing Institute of Technology Beijing Beijing Normal university Beijing Brown university ProvidenceRI Budker Institute of Nuclear Physics Novosibirsk Cadi Ayyad university Laboratory of Fundamental and Applied PhysicsPolydisciplinary FacultyMarrakech Cairo university Giza Center for Theory and Computation National Tsing Hua UniversityHsinchu Central china Normal university WuhanHubei Central South university ChangshaHunan Centro de Fisica Teorica de Particulas Universidade Tecnica de LisboaLisboa Chengdu KaitengSifang Digital Radio&TV Equipment Co. LtdChengduSichuan china academy of engineering physics MianyangSichuan china building materials academy Beijing china Center of Advanced Science and Technology Beijing china Institute of Atomic Energy Beijing china Jiliang university HangzhouZhejiang china Nuclear Instrument CO. LTDBeijing china university of Geosciences Beijing china university of Geosciences WuhanHubei china university of Mining and Technology XuzhouJiangsu china West Normal university NanchongSichuan Chongqing university Department of PhysicsChongqing Chulalongkorn university Bangkok City university of Hong Kong Department of PhysicsHong Kong Cockcroft Institute Daresbury Cornell university IthacaNY CPPM(AMU/IPhU&CNRS/INP) Marseille dalian Minzu university DalianLiaoning dalian university of Technology Department of PhysicsDalian Deutsches Elektronen-Synchrotron DESY Hamburg Dzhelepov Laboratory of Nuclear Problems of Joint Institute for Nuclear Research(DLNP jinR) Dubna East china university Of Science And Technol

The Circular Electron Positron Collider(CEPC)is a large scientific project initiated and hosted by china,fostered through extensive collaboration with international *** complex comprises four accelerators:a 30 GeV linac,a 1.1 GeV damping Ring,a Booster capable of achieving energies up to 180 GeV,and a Collider operating at varying energy modes(Z,W,H,and tt).The linac and damping Ring are situated on the surface,while the subterranean Booster and Collider are housed in a 100 km circumference underground tunnel,strategically accommodating future expansion with provisions for a potential Super Proton Proton Collider(SPPC).The CEPC primarily serves as a Higgs *** its baseline design with synchrotron radiation(SR)power of 30 MW per beam,it can achieve a luminosity of 5×10^(34)cm^(-2)s^(-1)per interaction point(IP),resulting in an integrated luminosity of 13 ab^(-1)for two IPs over a decade,producing 2.6 million Higgs *** the SR power to 50 MW per beam expands the CEPC's capability to generate 4.3 million Higgs bosons,facilitating precise measurements of Higgs coupling at sub-percent levels,exceeding the precision expected from the HL-LHC by an order of *** Technical Design Report(TDR)follows the Preliminary Conceptual Design Report(Pre-CDR,2015)and the Conceptual Design Report(CDR,2018),comprehensively detailing the machine's layout,performance metrics,physical design and analysis,technical systems design,R&D and prototyping efforts,and associated civil engineering ***,it includes a cost estimate and a preliminary construction timeline,establishing a framework for forthcoming engineering design phase and site selection *** is anticipated to begin around 2027-2028,pending government approval,with an estimated duration of 8 *** commencement of experiments and data collection could potentially be initiated in the mid-2030s.

关键词： initiated exceeding precise

Clinical practice guideline for transurethral plasmakinetic resection of prostate for benign prostatic hyperplasia(2021 Edition)

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Military medical Research 2022年第5期9卷 515-533页

作者： Xian-Tao Zeng Ying-Hui jin Tong-Zu liu fang-ming Chen De-Gang Ding Meng Fu Xin-Quan gu Bang-Min Han Xing Huang Zhi Hou wan-li Hu Xin-li Kang Gong-Hui li jian-Xing li Pei-jun li Chao-Zhao liang Xiu-Heng liu Zhi-Yu liu Chun-Xiao liu Jiu-Min liu guang-Heng Luo Yi Luo wei-jun Qin jian-Hong Qiu jian-Xin Qiu Xue-jun Shang Ben-Kang Shi Fa Sun guo-Xiang Tian Ye Tian Feng wang Feng wang Yin-Huai wang Yu-Jie wang Zhi-Ping wang Zhong wang Qiang wei Min-Hui Xiao wan-Hai Xu Fa-Xian Yi Chao-Yang Zhu Qian-Yuan Zhuang li-Qun Zhou Xiao-Feng Zou Nian-Zeng Xing da-lin He Xing-Huan wang 无 Department of Urology Institute of UrologyZhongnan Hospital of Wuhan UniversityWuhan430071China Center for Evidence-Based and Translational Medicine Zhongnan Hospital of Wuhan UniversityWuhan430071China Department of Urology Tianjin Third Central Hospital Affiliated To Nankai UniversityTianjin300170China Department of Urology Henan Provincial People’s HospitalZhengzhou University People’s HospitalZhengzhou450003China Department of Urology Beijing Tsinghua Changgung HospitalSchool of Clinical MedicineTsinghua UniversityBeijing102218China Department of Urology China-Japan Union Hospital of Jilin UniversityChangchun130033China Department of Urology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghai200080China Department of Urology Qinghai University Affiliated HospitalXi’ning810012China Department of Urology People’s Hospital of Hainan ProvinceHainan Affiliated Hospital of Hainan Medical University HaikouHaikou570311China Department of Urology Sir Run Run Shaw HospitalZhejiang University School of MedicineHangzhou310016China Department of Urology General Hospital of Ningxia Medical UniversityYinchuan750003China Department of Urology The First Affiliated Hospital of Anhui Medical UniversityHefei230022China Department of Urology Renmin Hospital of Wuhan UniversityWuhan430060China Department of Urology The Second Hospital of Dalian Medical UniversityDalian116023LiaoningChina Department of Urology Zhujiang Hospital of Southern Medical UniversityGuangzhou510282China Department of Urology Guangdong Provincial People’s HospitalGuangdong Academy of Medical SciencesGuangzhou510080China Department of Urology Surgery Guizhou Province People’s HospitalGuiyang550002China Department of Urology Xijing Hospital of Air Force Military Medical UniversityXi’an710032China Department of Urology The 980St Hospital of the PLA Joint Logistics Support Force(Bethune International Peace Hospital of PLA)Shijiazhuang050082China Department of Urology

Benign prostatic hyperplasia (BPH) is highly prevalent among older men, impacting on their quality of life, sexual function, and genitourinary health, and has become an important global burden of disease. Transurethral plasmakinetic resection of prostate (TUPKP) is one of the foremost surgical procedures for the treatment of BPH. It has become well established in clinical practice with good efficacy and safety. In 2018, we issued the guideline “2018 Standard Edition”. However much new direct evidence has now emerged and this may change some of previous recommendations. The time is ripe to develop new evidence-based guidelines, so we formed a working group of clinical experts and methodologists. The steering group members posed 31 questions relevant to the management of TUPKP for BPH covering the following areas: questions relevant to the perioperative period (preoperative, intraoperative, and postoperative) of TUPKP in the treatment of BPH, postoperative complications and the level of surgeons’ surgical skill. We searched the literature for direct evidence on the management of TUPKP for BPH, and assessed its certainty generated recommendations using the grade criteria by the European Association of Urology. Recommendations were either strong or weak, or in the form of an ungraded consensus-based statement. Finally, we issued 36 statements. Among them, 23 carried strong recommendations, and 13 carried weak recommendations for the stated procedure. They covered questions relevant to the aforementioned three areas. The preoperative period for TUPKP in the treatment of BPH included indications and contraindications for TUPKP, precautions for preoperative preparation in patients with renal impairment and urinary tract infection due to urinary retention, and preoperative prophylactic use of antibiotics. Questions relevant to the intraoperative period incorporated surgical operation techniques and prevention and management of bladder explosion. The application to different

关键词： Transurethral plasmakinetic resection of prostate Benign prostatic hyperplasia Recommendation Treatment guideline

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & pancreatic Diseases International 2022年第2期21卷 106-112页

作者： ren-Yi Su Sun-Bin ling Qiao-Nan Shan Xu-Yong wei Rui wang Chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-dan Xu Lai-Bang Luo li-Bo Sun guang-ming li Tai-Shi fang Nan jiang Kun Zhang Zhao-Jie Su Zhi-Hai Peng ren Lang Tao jiang Qiang He lin-Sen Ye Yang Yang Yu-Ting He Wen-Zhi guo liu-Gen Lan Xu-Yong Sun dong Chen Zhi-Shui Chen da-wei Zhou Shao-jun Ye Qi-Fa Ye Min Tian jian-Hua Shi Bo wang jiang liu Qian Lu wei Rao jin-Zhen Cai Tao Lv Jia-Yin Yang Pu-Sen wang lin Zhong jing-Sheng Ma Qi-Gen li Sheng-dong Wu Chang-jiang Lu Cai-De Lu dong-Hua Zhang Xuan wang Zi-Qiang li Mu-jian Teng jun-Jie li Wen-Tao jiang jian-Hua li Quan-Bao Zhang ning-Qi Zhu Zheng-Xin wang Kang He Qiang Xia Shao-Hua Song Zhi-ren Fu wei Qiu guo-Yue Lv Rui-Peng Song Ji-Zhou wang Zheng wang jian Zhou Gang Chen Ying-Peng Zhao li li Ze-Min Hu Qi-Jie Luo Zhong-Zhou Si Bin Xie Xiao-Shun He Zhi-Yong guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan university Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion

Timing analysis of the black hole candidate EXO 1846–031 with Insight-HXMT monitoring

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2021年第3期21卷 193-204页

作者： He-Xin liu Yue Huang guang-Cheng Xiao Qing-Cui Bu jin-Lu Qu Shu Zhang Shuang-Nan Zhang Shu-Mei Jia fang-jun Lu Xiang Ma lian Tao wei Zhang li Chen li-ming Song Ti-Pei li Yu-Peng Xu Xue-Lei Cao Yong Chen Cong-Zhan liu Ce Cai Zhi Chang Gang Chen Tian-Xiang Chen Yi-Bao Chen Yu-Peng Chen wei Cui wei-wei Cui jing-Kang Deng Yong-wei dong Yuan-Yuan Du Min-Xue Fu guan-Hua Gao He Gao Min Gao ming-Yu Ge Yu-dong gu Ju guan Cheng-Cheng guo da-wei Han Jia Huo Lu-Hua jiang wei-Chun jiang jing jin Yong-Jie jin ling-da Kong Bing li Cheng-Kui li Gang li Mao-Shun li wei li Xian li Xiao-Bo li Xu-fang li Yang-guo li Zheng-wei li Xiao-Hua liang jing-Yuan liao Bai-Sheng liu guo-Qing liu Hong-wei liu Xiao-jing liu Yi-Nong liu Bo Lu Xue-Feng Lu Qi Luo Tao Luo Bin Meng Yi Nang jian-Yin Nie Ge Ou Na Sai ren-Cheng Shang Xin-Ying Song liang Sun Ying Tan You-li Tuo Chen wang guo-Feng wang Juan wang ling-jun wang Weng-Shuai wang Yu-Sa wang Xiang-Yang Wen Bai-Yang Wu Bo-Bing Wu Mei Wu Shuo Xiao Shao-lin Xiong He Xu Jia-wei Yang Sheng Yang Yan-Ji Yang Yi-jung Yang Qi-Bin Yi Qian-Qing Yin Yuan You Ai-Mei Zhang Cheng-Mo Zhang Fan Zhang Hong-Mei Zhang Juan Zhang Tong Zhang wan-Chang Zhang Wen-Zhao Zhang Yi Zhang Yi-Fei Zhang Yong-Jie Zhang Yuan-Hang Zhang Yue Zhang Zhao Zhang Zhi Zhang Zi-liang Zhang Hai-Sheng Zhao Xiao-Fan Zhao Shi-Jie Zheng yao-guang Zheng Deng-Ke Zhou jian-Feng Zhou Yu-Xuan Zhu ren-lin Zhuang Yue Zhu Key Laboratory of Particle Astrophysics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China university of Chinese Academy of Sciences Chinese Academy of SciencesBeijing 100049China Institut fur Astronomie und Astrophysik Kepler Center for Astro and Particle PhysicsEberhard Karls Universität72076 TubingenGermany Department of Astronomy Beijing Normal UniversityBeijing 100088China Department of Astronomy Tsinghua UniversityBeijing 100084China Department of Physics Tsinghua UniversityBeijing 100084China Department of Engineering Physics Tsinghua UniversityBeijing 100084China Key Laboratory of Space Astronomy and Technology National Astronomical ObservatoriesChinese Academy of SciencesBeijing 100101China college of Physics Sciences&Technology Hebei UniversityBaoding 071002Hebei ProvinceChina

We present the observational results from a detailed timing analysis of the black hole candidate EXO 1846-031 during its outburst in 2019 with the observations of Insight-HXMT,NICER and *** outburst can be classified roughly into four different ***-C quasi-periodic oscillations(QPOs)observed by NICER(about 0.1-6 Hz)and Insight-HXMT(about 0.7-8 Hz)are also reported in this ***,we study various physical quantities related to QPO *** QPO rms-frequency relationship in the energy band 1-10 keV indicates that there is a turning pointing in frequency around2 Hz,which is similar to that of GRS 1915+105.A possible hypothesis for the relationship above may be related to the inclination of the source,which may require a high inclination to explain *** relationships between QPO frequency and QPO rms,hardness,total fractional rms and count rate have also been found in other transient sources,which can indicate that the origin of type-C QPOs is non-thermal.

关键词： X-ray binaries black hole candidate QPO EXO 1846–031

在线全文

学校读者我要写书评

暂无评论

注射用丹参多酚酸盐的药学综合评价

中国药学杂志 2021年第5期56卷 422-428页

作者：韩晟赵熙子史录文林丽开李大魁陈凯先宣利江马传江马海英方唯一王丽霞文爱东付秀娟左燕刘小玲刘向红刘国强朱珠陈万生陈维红吴方建吴玉波吴晖张伟张毕奎林慧周国华欧阳荣胡元会姜明燕赵春景贾乐川晋月萍唐洪梅曹俊岭梁春商洪才董占军董吁钢翟所迪北京大学医药管理国际研究中心北京100191 武汉大学中南医院武汉大学医院管理研究所武汉430071 北京协和医院北京100730 中国科学院上海药物研究所上海201203 山东中医药大学附属医院济南250014 中国医科大学附属第四医院沈阳110000 复旦大学附属华东医院上海200030 中国中医科学院广安门医院北京100053 中国人民解放军空军军医大学第一附属医院西安710032 吉林大学第二医院长春130041 陕西省人民医院西安710068 内蒙古自治区人民医院呼和浩特010017 山东大学齐鲁医院济南250012 河北医科大学第三医院石家庄050051 上海长征医院上海200003 山西白求恩医院(山西医学科学院) 太原030032 长江航运总医院武汉430015 哈尔滨医科大学附属第四医院哈尔滨150001 昆明医科大学第一附属医院昆明650032 河南省人民医院郑州450003 中南大学湘雅二医院长沙410011 海南省药学会海口570102 南京大学医学院附属金陵医院南京210000 湖南中医药大学第一附属医院长沙410007 中国医科大学附属第一医院沈阳110001 重庆医科大学附属第二医院重庆400000 宁夏医科大学总医院宁夏750004 山西医科大学第一医院太原030001 广州中医药大学第一附属医院广州510405 北京中医药大学东方医院北京100078 北京中医药大学东直门医院北京100007 河北省人民医院石家庄050051 中山大学附属第一医院广州510080 北京大学第三医院北京100191

目的以注射用丹参多酚酸盐为例,探索中药注射剂的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从药学特性、质量等方面对注射用丹参多酚酸盐进行药学综合评价。结果在有效成分和药物作用机... 详细信息

目的以注射用丹参多酚酸盐为例,探索中药注射剂的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从药学特性、质量等方面对注射用丹参多酚酸盐进行药学综合评价。结果在有效成分和药物作用机制方面,丹参多酚酸盐已经进行了大量的基础研究。质量方面的文献证据也较为丰富。结论注射用丹参多酚酸盐在药学特性方面研究探索面非常广,相关基础研究还有待进一步探索。

关键词：丹参酚酸B 综合评价中药注射剂药学特性

在线全文

学校读者我要写书评

暂无评论

注射用丹参多酚酸盐的临床应用综合评价

中国药学杂志 2021年第6期56卷 507-514页

作者：韩晟赵熙子史录文林丽开李大魁陈凯先宣利江马传江马海英方唯一王丽霞文爱东付秀娟左燕刘小玲刘向红刘国强朱珠陈万生陈维红吴方建吴玉波吴晖张伟张毕奎林慧周国华欧阳荣胡元会姜明燕赵春景贾乐川晋月萍唐洪梅曹俊岭梁春商洪才董占军董吁钢翟所迪北京大学医药管理国际研究中心北京100191 武汉大学中南医院武汉大学医院管理研究所武汉430071 北京协和医院北京100730 中国科学院上海药物研究所上海201203 山东中医药大学附属医院济南250014 中国医科大学附属第四医院沈阳110000 复旦大学附属华东医院上海200030 中国中医科学院广安门医院北京100053 中国人民解放军空军军医大学第一附属医院西安710032 吉林大学第二医院长春130041 陕西省人民医院西安710068 内蒙古自治区人民医院呼和浩特010017 山东大学齐鲁医院济南250012 河北医科大学第三医院石家庄050051 海军军医大学第二附属医院上海200003 山西白求恩医院(山西医学科学院) 太原030032 长江航运总医院武汉430015 哈尔滨医科大学附属第四医院哈尔滨150001 昆明医科大学第一附属医院昆明650032 河南省人民医院郑州450003 中南大学湘雅二医院长沙410011 海南省药学会海口570102 南京大学医学院附属金陵医院南京210000 湖南中医药大学第一附属医院长沙410007 中国医科大学附属第一医院沈阳110001 重庆医科大学附属第二医院重庆400010 宁夏医科大学总医院银川750004 山西医科大学第一医院太原030001 广州中医药大学第一附属医院广州510405 北京中医药大学东方医院北京100078 北京中医药大学东直门医院北京100007 河北省人民医院石家庄050051 中山大学附属第一医院广州510080 北京大学第三医院北京100191

目的以注射用丹参多酚酸盐为例,探索中药注射剂临床应用的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从有效性、安全性、经济性、顺应性和标签信息等方面对注射用丹参多酚酸盐进行系统综... 详细信息

目的以注射用丹参多酚酸盐为例,探索中药注射剂临床应用的综合评价方法,为今后相关工作的开展和完善提供参考。方法通过文献检索和获取相关文献资料,从有效性、安全性、经济性、顺应性和标签信息等方面对注射用丹参多酚酸盐进行系统综合评价。结果除说明书适应证外,丹参多酚酸盐在心血管疾病、脑血管疾病等多种超说明书适应证中都存在具有一定质量的临床研究证据;在安全性、经济性方面的文献证据较为丰富。结论注射用丹参多酚酸盐在有效性、安全性及经济性等方面的临床研究证据较多,且具有一定的体系。但作为一个临床应用大品种,该药依然需要在一些方面做出更多的研究努力。

关键词：丹参酚酸B镁药品综合评价中药注射剂有效性安全性

在线全文

学校读者我要写书评

暂无评论

复方氨基酸注射液临床应用专家共识

肿瘤代谢与营养电子杂志 2019年第2期6卷 183-189页

作者：高纯李梦韦军民李玉珍田伟军姜海平沈威许爱国余震陈东生陈莲珍管文贤江华李大魁梅丹于吉人赵春临范伟胡松康焰康维明吕传柱刘东刘辉吕永宁孟翔凌宋金春孙明伟汤庆娅王烈王景杰吴东方许媛徐华颜伟慧闫雪莲曾俊张片红龚建平郭增清胡俊波孟庆华李增宁钱素云秦宝丽沈荣田字彬许红霞姚颖于乐成石汉平华中科技大学同济医学院附属同济医院北京医院 /国家老年医学中心北京大学人民医院天津医科大学总医院暨南大学附属第一医院南昌大学第二附属医院郑州大学第一附属医院同济大学附属第十人民医院华中科技大学同济医学院附属协和医院国家癌症中心 /国家肿瘤临床医学中心 /中国医学科学院北京协和医学院肿瘤医院南京大学医学院附属鼓楼医院四川省医学科学院·四川省人民医院北京协和医院浙江大学医学院附属第一医院贵州省人民医院武汉市第一医院四川大学华西医院海南医学院中国人民解放军中部战区总医院安徽医科大学第一附属医院武汉大学人民医院上海交通大学医学院附属新华医院中国人民解放军联勤部第 900 医院空军军医大学唐都医院武汉大学中南医院北京清华长庚医院武汉儿童医院浙江大学医学院附属第二医院福建省肿瘤医院 /福建医科大学附属肿瘤医院首都医科大学附属北京佑安医院河北医科大学第一医院首都医科大学附属北京儿童医院辽宁省肿瘤医院浙江大学公共卫生学院青岛大学附属医院陆军军医大学大坪医院东部战区总医院南京中医药大学附属八一医院首都医科大学附属北京世纪坛医院中华医学会肠外肠内营养学分会中国抗癌协会肿瘤营养专业委员会

复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了... 详细信息

复方氨基酸注射液是肠外营养中氮的来源,广泛应用于不能经胃肠道给予或经胃肠道给予不能满足其营养需求的患者,在营养治疗中起重要作用。但目前对于复方氨基酸注射液临床应用的指征、剂型、剂量、时机,国内并无系统的指南或共识。为了进一步规范复方氨基酸注射液的临床应用,中华医学会肠外肠内营养学分会(Chinese Society for Parenteral and Enteral Nutrition,CSPEN)及中国抗癌协会肿瘤营养专业委员会(Chinese Society of Nutritional Oncology,CSNO)组织全国专家,在系统性文献检索的基础上,参考美国肠外肠内营养学会(American Society for Parenteral and Enteral Nutrition,ASPEN)、欧洲临床营养和代谢学会(European Society for Clinical Nutrition and Metabolism,ESPEN)、CSPEN及CSNO指南,结合我国临床实践,经多次交流讨论,达成此共识。包括10条推荐意见,涉及不同患者的蛋白质需要量及氨基酸剂型选择。

关键词：复方氨基酸注射液肠外营养蛋白质营养治疗专家共识

新型冠状病毒感染者脊柱外科急诊手术的围手术期管理专家共识

在线全文

学校读者我要写书评

暂无评论

脊柱外科杂志 2020年第6期18卷 361-368页

作者：华文彬郜勇李危石仉建国朱泽章王冰李方财何达马真胜魏欣杨磊任东平张雪松李利吴继功徐宝山宁广智武汉杨群戈朝晖康学文夏磊高延征刘新宇刘浩初同伟熊伟夏平陈雄生白玉树殷国勇王向阳刘向阳杨军林万勇董健文丁文元陶惠人王迎松吴星火张宇坤郑东潘海涛吴永超曾宪林李锋邵增务杨述华邱海波王征杨操华中科技大学同济医学院附属协和医院骨科武汉430022 北京大学第三医院骨科北京100191 北京协和医院骨科北京100032 南京大学医学院附属鼓楼医院骨科南京210008 中南大学湘雅二医院骨科长沙410011 浙江大学医学院附属第二医院骨科杭州310056 北京积水潭医院骨科北京100035 空军军医大学西京医院骨科西安710032 华中科技大学同济医学院附属协和医院麻醉科武汉430022 华中科技大学同济医学院附属协和医院手术室武汉430022 中国人民解放军总医院骨科北京100853 中国人民解放军战略支援部队特色医学中心骨科北京100010 天津医院骨科天津300211 天津医科大学总医院骨科天津300052 吉林大学中日联谊医院骨科长春130033 大连医科大学附属第一医院骨科大连116011 宁夏医科大学总医院骨科银川750004 兰州大学第二医院骨科兰州730000 郑州大学第一附属医院骨科郑州450052 河南省人民医院骨科郑州450003 山东大学齐鲁医院骨科济南250012 四川大学华西医院骨科成都610041 陆军军医大学新桥医院骨科重庆400037 华中科技大学同济医学院附属同济医院骨科武汉430030 武汉市第一医院骨科武汉430022 海军军医大学附属长征医院骨科上海200003 海军军医大学附属长海医院骨科上海200433 南京医科大学第一附属医院骨科南京210029 温州医科大学附属第二医院骨科温州325000 湖南省人民医院骨科长沙410002 上海交通大学医学院附属新华医院骨科上海200092 中山大学附属第一医院骨科广州510080 中山大学附属第三医院骨科广州510630 河北医科大学第三医院骨科石家庄050091 深圳大学总医院骨科深圳518055 昆明医科大学附属第二医院骨科昆明650031 东南大学附属中大医院重症医学科南京210009

自2019年12月以来,已有200余个国家和地区相继报道了新型冠状病毒感染病例,世界卫生组织(WHO)于2020年3月12日宣布新型冠状病毒全球大流行,截至6月18日,全球已累计有824万余人感染,44万余人死亡,对全世界医疗、政治和经济领域影响巨大[1... 详细信息

自2019年12月以来,已有200余个国家和地区相继报道了新型冠状病毒感染病例,世界卫生组织(WHO)于2020年3月12日宣布新型冠状病毒全球大流行,截至6月18日,全球已累计有824万余人感染,44万余人死亡,对全世界医疗、政治和经济领域影响巨大[1-2]。WHO将其命名为“2019冠状病毒感染性疾病”(COVID-19),病原体被命名为重症急性呼吸综合征冠状病毒2(SARS-CoV-2)[3-6]。按照《中华人民共和国传染病防治法》,COVID-19被纳入乙类传染病,采取甲类传染病的预防控制措施[7]。

关键词：脊柱疾病冠状病毒感染肺炎,病毒性急诊处理外科手术